ACAD
31.936
+0.496
+1.5782%
AEMD
1.517
+0.097
+6.8380%
APRI
1.516
+0.036
+2.4392%
ARNA
21.12
+0.1
+0.48%
ATEC
1.916
-0.004
-0.208%
CNAT
5.22
+0.04
+0.77%
CRXM
0.172
0.00
0.00%
CYTX
0.318
-0.003
-0.837074%
DXCM
75.51
-0.4
-0.53%
GNMK
9.52
+0.08
+0.85%
HALO
12.1
0.00
0.00%
ILMN
192.78
-1.98
-1.02%
INNV
0.112
-0.005
-4.1026%
INO
5.615
+0.055
+0.989%
ISCO
1.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
127.415
-0.555
-0.434%
LPTN
2.93
-2.93
-100.00%
MBVX
0.481
-0.029
-5.6078%
MEIP
2.554
-0.026
-1.0116%
MNOV
5.08
+0.03
+0.59%
MRTX
5.025
-0.275
-5.189%
MSTX
0.13
-0.01
-5.28%
NBIX
52.11
-0.55
-1.04%
NUVA
63.71
-0.99
-1.53%
ONCS
0.93
-0.01
-1.0532%
ONVO
1.889
-0.061
-3.128%
OREX
2.38
+0.04
+1.71%
OTIC
20.275
-0.075
-0.369%
QDEL
33.205
-0.275
-0.8220%
RCPT
231.96
0.00
0.00%
RGLS
0.918
+0.058
+6.6860%
RMD
74.035
-0.515
-0.691%
SCIE
0
0.00
0.00%
SPHS
1.92
+0.03
+1.59%
SRNE
1.65
-0.05
-2.94%
TROV
0.834
-0.017
-1.9412%
VICL
2.33
-0.04
-1.69%
VOLC
18
0.00
0.00%
ZGNX
12.55
+0.1
+0.80%
ACAD
31.936
+0.496
+1.5782%
AEMD
1.517
+0.097
+6.8380%
APRI
1.516
+0.036
+2.4392%
ARNA
21.12
+0.1
+0.48%
ATEC
1.916
-0.004
-0.208%
CNAT
5.22
+0.04
+0.77%
CRXM
0.172
0.00
0.00%
CYTX
0.318
-0.003
-0.837074%
DXCM
75.51
-0.4
-0.53%
GNMK
9.52
+0.08
+0.85%
HALO
12.1
0.00
0.00%
ILMN
192.78
-1.98
-1.02%
INNV
0.112
-0.005
-4.1026%
INO
5.615
+0.055
+0.989%
ISCO
1.2
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
127.415
-0.555
-0.434%
LPTN
2.93
-2.93
-100.00%
MBVX
0.481
-0.029
-5.6078%
MEIP
2.554
-0.026
-1.0116%
MNOV
5.08
+0.03
+0.59%
MRTX
5.025
-0.275
-5.189%
MSTX
0.13
-0.01
-5.28%
NBIX
52.11
-0.55
-1.04%
NUVA
63.71
-0.99
-1.53%
ONCS
0.93
-0.01
-1.0532%
ONVO
1.889
-0.061
-3.128%
OREX
2.38
+0.04
+1.71%
OTIC
20.275
-0.075
-0.369%
QDEL
33.205
-0.275
-0.8220%
RCPT
231.96
0.00
0.00%
RGLS
0.918
+0.058
+6.6860%
RMD
74.035
-0.515
-0.691%
SCIE
0
0.00
0.00%
SPHS
1.92
+0.03
+1.59%
SRNE
1.65
-0.05
-2.94%
TROV
0.834
-0.017
-1.9412%
VICL
2.33
-0.04
-1.69%
VOLC
18
0.00
0.00%
ZGNX
12.55
+0.1
+0.80%
Home » Archive by Category

Syndication

Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis

August 23, 2017 – 6:00 am

— MODIFY2 study will evaluate efficacy in pain management for patients with mild-to-moderate osteoarthritis of the knee —- Concurrent MODIFY-MRI imaging study will assess short-term physical modifications of the disease process —

SAN FRANCISCO, Aug. 23, 2017 /PRNewswire/ — Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of the 12-week, multicenter, double-blinded trial of approximately 60 patients follows previously announced Phase 1/2a clinical results supporting the safety, tolerability and intended mechanism of action of SB-061. In addition, Symic Bio plans to conduct a concurrent magnetic resonance imaging study, MODIFY-MRI, to assess the short-term physical modifications of the disease process resulting from SB-061 treatment. The MODIFY-MRI study includes an assessment of the process of inflammation, intended to provide data that are critical in further defining the potential for SB-061 to act as a long-term disease-modifying agent.

“We are encouraged by the performance of SB-061 in the clinic thus far,” said Nathan Bachtell, M.D., Chief Medical Officer of Symic Bio. “By addressing the degradation of cartilage that is fundamental to disease pathology, SB-061 is intended to both manage pain and modify the course of disease. We are looking forward to efficacy results and MRI imaging data and expect to provide a top-line analysis of MODIFY2 and MODIFY-MRI results in early 2018.”

Additional information on the design of SB-061 for the treatment of osteoarthritis can be found at https://youtu.be/LNiHLtMiV8s or www.symic.bio/pipeline/osteoarthritis/.

SB-061 from Symic Bio

In the osteoarthritis disease state, the primary proteoglycan in the cartilage extracellular matrix, aggrecan, is degraded and lost. With the loss of aggrecan, cartilage is vulnerable to pro-inflammatory cytokines that cause degradation, leading to additional breakdown of the extracellular matrix in the joint. SB-061, a therapeutic bioconjugate inspired by aggrecan, is a drug delivered directly to the joint via an intra-articular injection. SB-061 directly targets the degrading extracellular matrix, thereby reducing the inflammatory cycle that drives the signs and symptoms of progressive osteoarthritis. The goal of this approach is to modify the course of disease by reducing joint degradation and concurrently decreasing pain and functional decline due to inflammation in the joint.

For more information on the MODIFY2 Phase 2 trial for osteoarthritis of the knee, please see https://clinicaltrials.gov/ct2/show/NCT03231280.

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company’s website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

 

View original content:http://www.prnewswire.com/news-releases/symic-bio-enrolls-first-patient-in-modify2-phase-2-trial-of-sb-061-for-the-treatment-of-osteoarthritis-300508236.html

SOURCE Symic Bio

Senior Research Associate

August 23, 2017 – 5:57 am

Job Description: A Research Organization is now hiring in Mira Mesa! This positions will entail extensive animal research on rats/mice and other larger mammals as well. Responsibilities: Organization and coordination of research projects. Schedule studies

Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board

August 23, 2017 – 5:23 am

– NFL CHAMPION WITH SEATTLE SEAHAWKS (2014)- NFL PLAYERS ASSOCIATION EXECUTIVE COMMITTEE MEMBER

SAN DIEGO, Aug. 23, 2017 /PRNewswire/ — Oxeia Biopharmaceuticals, Inc. announces Richard Sherman, cornerback of the Seattle Seahawks (National Football League), as a member of its Advisory Board.

“Richard is a passionate advocate for brain health and a star on and off the field.  As an active player in the NFL, Richard participates in a very rigorous concussion testing protocol each season. This direct experience will be invaluable to us as we enter clinical trials for our concussion drug treatment.  We look forward to working closely with Richard,” said Kartik Shah, Chief Business Officer for Oxeia Biopharmaceuticals.

Mr. Sherman joins an experienced pharmaceutical development team at Oxeia that is advised by leading medical experts from Stanford, UCSD, Harvard and the Concussion Legacy Foundation. The company is preparing to initiate a phase 2 clinical study in concussion patients with OXE-103. OXE-103 is an agent with well-established neuroprotective properties with an extensive safety record.

“The Oxeia team is at the forefront of concussion treatment innovation. As a professional football player, I am acutely aware of the risk posed by concussions – we need to start talking about, and working actively on solutions.  I look forward to assisting Oxeia as they develop an FDA-approvable treatment for concussions that is safe and effective,” said Mr. Sherman, cornerback, Seattle Seahawks.

Concussions induce a metabolic response within the brain resulting in an “energy crisis” as brain cells attempt to respond to the injury.  Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018.

Please visit www.oxeiabiopharma.com for more information and contact details.

About Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage biotechnology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions.

Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.

About Richard Sherman
Born in Compton, California, Mr. Sherman excelled both on the field as a football and track star, and in the classroom as salutatorian with a 4.2 GPA at Dominguez High School. After a stellar career at Stanford University, the outstanding cornerback was picked by the Seattle Seahawks in the fifth round in the 2011 NFL Draft.  Mr. Sherman anchored the defense and helped lead the Seahawks to back-to-back NFC Championships in 2013 and 2014, as well as their first NFL title in 2014. Mr. Sherman is a 4x Pro Bowler, 4x All-Pro, and took home the NFC Defensive Player of the Year title in 2014. Mr. Sherman has been an NFLPA Player Representative since September 2014.

Off the field, he started his charity – Blanket Coverage, The Richard Sherman Family Foundation – in 2013 in order to provide students in low-income communities with clothing and supplies to help them work towards achieving their goals. Mr. Sherman was nominated for the Walter Payton Man of the Year Award in 2015 because of his efforts in the community.

Contact:
Kartik Shah, Chief Business Officer
info@oxeiabiopharma.com
207-232-2863

 

View original content:http://www.prnewswire.com/news-releases/richard-sherman-nfl-all-pro-joins-oxeia-biopharmaceuticals-advisory-board-300508408.html

SOURCE Oxeia Biopharmaceuticals, Inc.

Pfenex To Present at the 6th Annual Liolios Gateway Conference on September 6th, 2017

August 23, 2017 – 4:00 am

SAN DIEGO, Aug. 23, 2017 /PRNewswire/ — Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 6th Annual Liolios Gateway Conference on September 6th, 2017 at 11:00 am PT. The conference will be held at the Four Seasons Hotel, San Francisco.  The presentation will be webcast and available for replay in the Investor Section of Pfenex’s website www.pfenex.com or on the Gateway Conference website www.gateway-conference.com/presenters.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com/), our investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company’s lead product candidates are PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis, and PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, therapeutic equivalents to reference listed drug products, and next generation biologics.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/pfenex-to-present-at-the-6th-annual-liolios-gateway-conference-on-september-6th-2017-300508165.html

SOURCE Pfenex Inc.

Fisheries Monitoring Data Management Services (LA JOLLA)

August 22, 2017 – 5:19 pm

Fisheries Monitoring Data Management Services
Ocean Associates, Inc. is seeking a qualified person to fill a Scientist III position, with education and experience in managing and maintaining fisheries data sets in an enterprise Oracle database with …

Research Associate

August 22, 2017 – 2:25 pm

BioPhase Solutions specializes in recruiting top talented professionals for California’s Scientific community. We are currently looking for a Clinical Lab Scientist to work for a leading Bay Area biotechnology company.
Research Associate
Summary:

Packaging Technician

August 22, 2017 – 1:13 pm

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego. Our mission is to accelerate research and discovery by providing the highest quality products at …

Packaging Technician

August 22, 2017 – 1:13 pm

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego. Our mission is to accelerate research and discovery by providing the highest quality products at …

MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and is Engaging an Advisory Bank to Explore Strategic Alternatives

August 22, 2017 – 12:05 pm

-Lead Investor Commits to Invest Additional $1.0M Upon Approval of Various Proposals in a Special Meeting of Stockholders to be Scheduled

SAN DIEGO, Aug. 22, 2017 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced the close of its securities purchase agreements with investors providing for the registered sale of approximately $1,312,500 of shares of Series J Convertible Preferred Stock, representing approximately 2,386.36 shares at a purchase price of $550 per share. The shares of preferred stock are convertible into 2,386,364 shares of the Company’s common stock, based on a fixed conversion price of $0.55 per share and a stated value of $550 per share. 

The total gross proceeds of the offering of approximately $1.3 million will be used for working capital and general corporate purposes.  Additionally, the lead investor committed to invest an additional $1.0 million following approval of a series of proposals in a special meeting of stockholders to be scheduled for a date on or about September 28, 2017.

The shares of Series J Convertible Preferred Stock, and the shares of common stock issuable upon conversion of the Series J Convertible Preferred Stock, were sold to the public under the Company’s shelf registration statement on Form S-3 (File No. 333-219291), initially filed with the Securities and Exchange Commission on July 14, 2017 and declared effective on July 27, 2017. The final prospectus supplement has been filed with the SEC and will form a part of the effective registration statement.

MabVax also announced that it is engaging a leading global independent investment bank to serve as a financial advisor to assist the Company in exploring and evaluating strategic options with the goal of maximizing shareholder value. The investment bank will be assisting the Company in evaluating transaction options currently being considered, which could include the acquisition of MabVax by another company, the sale or divestiture of specific assets, merging with another company, licensing of selected technologies or a combination of selected divestitures followed by a reverse merger.  MabVax does not have a defined timeline for the exploration of strategic alternatives and is not confirming that the evaluation will result in any strategic alternative being announced or consummated.  The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate.

“We have been taking deliberate steps to identify ways to secure the necessary capital to fund the Company in order to advance our pipeline.  While very challenging, we believe our financing strategy along with the opportunity to work with an investment bank that specializes in strategic transactions may provide the potential for the catalytic impact needed at this important time in the evolution of MabVax,” stated David Hansen, MabVax’s President and Chief Executive Officer. “We remain fully committed to advancing our lead product candidate, MVT-1075, a fully human antibody radioimmunotherapy (“RIT”) program in Phase 1 development for the treatment of CA19-9 positive malignancies including pancreatic, colon and lung cancers, from which we expect to report interim data by the end of this year. Moving forward, securing additional financing will enable us to further leverage our fully human antibody platform and prioritize our pipeline with the goal of addressing significant unmet medical needs for the treatment of cancer.”

The Company plans to schedule a special meeting of stockholders to be held on or about September 28, 2017, to approve (1) an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock by a ratio of not less than one-for-two, and not more than one-for-twenty at any time prior to one year from the date of the special meeting, with the exact ratio to be set as a whole number within this range as determined by the Board of Directors; (2) the potential issuance of up to 3,400,000 shares of common stock upon conversion of Series J Preferred Stock issued to investors in the financing consummated on August 14, 2017, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on August 14, 2017; (3) the potential issuance of up to 6,500,000 shares of common stock upon conversion of Series K Preferred Stock issued to investors in the financing consummated on August 14, 2017, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on August 14, 2017; (4) the issuance of securities in one or more non-public offerings where the maximum discount at which securities will be offered will be equivalent to a discount of 30% below the market price of the common stock, as required by and in accordance with Nasdaq marketplace Rule 5635(k); (5) the issuance of securities equivalent to a discount of 20% below the market price of the common stock, as required by and in accordance with Nasdaq Marketplace Rule 5635(d); and (6) the Fifth Amended and Restated MabVax Therapeutics Holdings, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan including authorization of the Board of Directors to pay an incentive bonus to management upon successful consummation of a transaction or series of transactions that cause a change in control of the Company.

Additionally, the Company announced that it has received a letter of notice from the Nasdaq Capital Market (the “Capital Market”) stating that as of August 15, 2017, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, and therefore no longer complies with the Nasdaq Listing Rule (the “Rule”) requiring companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing.

The decline in the Company’s stockholders’ equity was largely a result of planned expenditures related to Phase 1 clinical trials of the Company’s therapeutic antibody MVT-5873 and the PET diagnostic imaging product MVT-2163. A total of 50 patients with locally advanced or metastatic pancreatic cancer were treated with MVT-5873 or imaged with MVT-2163. The Phase 1 trial results from both studies were presented in June of 2017.  Results from both trials were highly encouraging demonstrating early safety, specificity for the target and a potential efficacy signal. The lead development program, the radioimmunotherapy product MVT-1075, has just entered the clinic in a Phase 1 dose escalation safety trial. While the two earlier Phase 1 trials were completed on time and within budget, clinical expenses exceeded the capital that was raised to perform the studies.

The Nasdaq has provided the Company with 45 calendar days, or until September 30, 2017, to submit a plan (the “Plan”) to regain compliance with the Rule. If the Plan is accepted, the Staff may grant an extension of up to 180 calendar days from the date of the notification letter (the “Maximum Extension”) to evidence compliance with the Rule.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction. Additional information can be found in the Company’s filings with the SEC available at www.sec.gov and on the Company’s website at www.mabvax.com.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety, specificity for the target and a potential efficacy signal. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company’s radioimmunotherapy product MVT-1075.  For additional information, please visit the Company’s website, www.mabvax.com.

Forward Looking Statements:

This press release on announcing the closing of our registered direct offering contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s clinical trials and product development pipeline. We have no assurance that all the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jtc@jenenethomascommunications.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/mabvax-therapeutics-holdings-inc-announces-the-closing-of-13-million-registered-direct-offering-and-is-engaging-an-advisory-bank-to-explore-strategic-alternatives-300507973.html

SOURCE MabVax Therapeutics Holdings, Inc.

SCIENTIFIC INTERN (part time) (La Jolla)

August 22, 2017 – 11:26 am

About Us
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare, diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date …